Incyte (INCY) Revenue Growth (5y) (2015 - 2026)
Incyte (INCY) Revenue Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.05% |
| Dec 31, 2025 | 13.80% |
| Sep 30, 2025 | 17.09% |
| Jun 30, 2025 | 12.05% |
| Mar 31, 2025 | 13.12% |
| Dec 31, 2024 | 15.26% |
| Sep 30, 2024 | 15.58% |
| Jun 30, 2024 | 14.52% |
| Mar 31, 2024 | 12.09% |
| Dec 31, 2023 | 13.91% |
| Sep 30, 2023 | 15.37% |
| Jun 30, 2023 | 12.85% |
| Mar 31, 2023 | 16.17% |
| Dec 31, 2022 | 15.85% |
| Sep 30, 2022 | 16.63% |
| Jun 30, 2022 | 22.79% |
| Mar 31, 2022 | 13.81% |
| Dec 31, 2021 | 21.45% |
| Sep 30, 2021 | 24.71% |
| Jun 30, 2021 | 23.43% |